Molnupiravir (Lagevrio) is currently approved by FDA for emergency use authorization for the treatment of COVID-19. It is a nucleoside analog that inhibits SARS-CoV-2 replication by viral mutagenesis. It is administered orally.
It is indicated for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, who are at high-risk for progression to severe COVID-19, including hospitalization or death.